Analytical Overview: DENTSPLY Sirona Inc (XRAY)’s Ratios Tell a Financial Story

Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

As of close of business last night, DENTSPLY Sirona Inc’s stock clocked out at $27.64, down -0.29% from its previous closing price of $27.72. In other words, the price has decreased by -$0.29 from its previous closing price. On the day, 1.4 million shares were traded. XRAY stock price reached its highest trading level at $27.99 during the session, while it also had its lowest trading level at $27.43.


To gain a deeper understanding of XRAY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.57. For the most recent quarter (mrq), Quick Ratio is recorded 0.97 and its Current Ratio is at 1.43. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.57.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on February 26, 2024, initiated with a Outperform rating and assigned the stock a target price of $42.

On November 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $35.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 31 ’24 when LUCIER GREGORY T bought 3,577 shares for $27.95 per share. The transaction valued at 99,976 led to the insider holds 58,374 shares of the business.

LUCIER GREGORY T bought 10,000 shares of XRAY for $314,400 on Nov 22 ’23. The Director now owns 43,121 shares after completing the transaction at $31.44 per share. On Nov 20 ’23, another insider, Coleman Glenn, who serves as the Executive VP & CFO of the company, bought 10,000 shares for $29.70 each. As a result, the insider paid 297,000 and bolstered with 73,566 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XRAY now has a Market Capitalization of 5738920960 and an Enterprise Value of 7680908800. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.46 while its Price-to-Book (P/B) ratio in mrq is 1.76. Its current Enterprise Value per Revenue stands at 1.949 whereas that against EBITDA is 12.25.

Stock Price History:

Over the past 52 weeks, XRAY has reached a high of $41.65, while it has fallen to a 52-week low of $26.27. The 50-Day Moving Average of the stock is -7.47%, while the 200-Day Moving Average is calculated to be -15.33%.

Shares Statistics:

It appears that XRAY traded 3.47M shares on average per day over the past three months and 2554790 shares per day over the past ten days. A total of 207.20M shares are outstanding, with a floating share count of 205.51M. Insiders hold about 1.02% of the company’s shares, while institutions hold 103.23% stake in the company. Shares short for XRAY as of 1715731200 were 12052394 with a Short Ratio of 3.48, compared to 1713139200 on 11933298. Therefore, it implies a Short% of Shares Outstanding of 12052394 and a Short% of Float of 6.6300004999999995.

Dividends & Splits

With its trailing 12-month dividend rate of 0.58, XRAY has a forward annual dividend rate of 0.58. Against a Trailing Annual Dividend Yield of 0.020923521The stock’s 5-year Average Dividend Yield is 1.08.

Earnings Estimates

The current market rating for DENTSPLY Sirona Inc (XRAY) reflects the collective analysis of 12.0 analysts closely monitoring its performance.On average, analysts expect EPS of $0.5 for the current quarter, with a high estimate of $0.52 and a low estimate of $0.45, while EPS last year was $0.51. The consensus estimate for the next quarter is $0.52, with high estimates of $0.57 and low estimates of $0.45.

Analysts are recommending an EPS of between $2.06 and $2.0 for the fiscal current year, implying an average EPS of $2.02. EPS for the following year is $2.37, with 14.0 analysts recommending between $2.57 and $2.24.

Revenue Estimates

In the current quarter, 12 analysts expect revenue to total $998.73M. It ranges from a high estimate of $1.03B to a low estimate of $981M. As of the current estimate, DENTSPLY Sirona Inc’s year-ago sales were $1.03BFor the next quarter, 12 analysts are estimating revenue of $955.63M. There is a high estimate of $985.2M for the next quarter, whereas the lowest estimate is $943M.

A total of 13 analysts have provided revenue estimates for XRAY’s current fiscal year. The highest revenue estimate was $4B, while the lowest revenue estimate was $3.9B, resulting in an average revenue estimate of $3.94B. In the same quarter a year ago, actual revenue was $3.96BBased on 14 analysts’ estimates, the company’s revenue will be $4.08B in the next fiscal year. The high estimate is $4.17B and the low estimate is $4.01B.

Most Popular